

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating spastic disorders, said method comprising administering to a subject having a spastic disorder a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or ~~compounds~~ a compound which yield yields gamma-aminobutyramide as an intermediate, a metabolite, or a by-product with the proviso the compound is not [α-(chloro-4'phenyl) fluoro-5' hydroxy-2-benzylidene-amino]4-butylamide.
2. (Original) A method according to claim 1, wherein said administering step further comprises intrathecally delivering the compound.
3. (Original) A method according to claim 1, wherein said administering step further comprises intraventricularly delivering the compound.
4. (Currently Amended) A method ~~according to claim 1, of treating spastic disorders, said method comprising administering to a subject having a spastic disorder a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or a compound which yields gamma-aminobutyramide as an intermediate, a metabolite, or a by-product~~ wherein the compound which yields gamma-aminobutyramide as a solubility product comprises 4-[[[4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

5. (Original) A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.

6. (Original) A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through a spinal catheter.

7. (Original) A method according to claim 1, wherein the spastic disorder is spastic hypertonia.

8. (Original) A method according to claim 1, wherein the spastic disorder is dystonia.

9. (Original) A method according to claim 1, wherein the spasticity or spastic disorder is caused by traumatic brain injury.

10. (Original) A method according to claim 2, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.

11. (Currently Amended) A method for treating convulsions, said method comprising administering to a subject either having convulsions or predisposed to convulsions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or

compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product with the proviso the compound is not [α-(chloro-4'phenyl) fluoro-5' hydroxy-2-benzylidene-amino]-4-butylamide.

12. (Original) A method according to claim 11, wherein said administering step further comprises intrathecally delivering the compound.

13. (Original) A method according to claim 11, wherein said administering step further comprises intraventricularly delivering the compound.

14. (Currently Amended) A method ~~according to claim 11, for treating convulsions,~~ said method comprising administering to a subject either having convulsions or predisposed to convulsions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product wherein the compound which yields gamma-aminobutyramide as a solubility product comprises 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino]butanamide.

15. (Original) A method according to claim 11, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.

16. (Original) A method according to claim 11, wherein said administering step further comprises delivering the compound to the subject through a catheter.

17. (Original) A method according to claim 12, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.

18. (Currently Amended) A method for treating epilepsy, said method comprising intraventricularly administering a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product with the proviso the compound is not [α-(chloro-4'phenyl) fluoro-5' hydroxy-2-benzylidene-amino]-4-butamide.

Claims 19-25 (Cancelled)

26. (Original) A method of treating idiopathic dystonia or torsional dystonia, said method comprising administering to a subject having idiopathic dystonia or torsional dystonia a therapeutically effective amount of gamma-aminobutyramide.

27. (New) A method according to claim 4, wherein said administering step further comprises intrathecally delivering the compound.

28. (New) A method according to claim 4, wherein said administering step further comprises intraventricularly delivering the compound.

29. (New) A method according to claim 4, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.
30. (New) A method according to claim 4, wherein said administering step further comprises delivering the compound to the subject through a spinal catheter.
31. (New) A method according to claim 4, wherein the spastic disorder is spastic hypertonia.
32. (New) A method according to claim 4, wherein the spastic disorder is dystonia.
33. (New) A method according to claim 4, wherein the spasticity or spastic disorder is caused by traumatic brain injury.
34. (Original) A method according to claim 27, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.
35. (New) A method according to claim 14, wherein said administering step further comprises intrathecally delivering the compound.

36. (New) A method according to claim 14, wherein said administering step further comprises intraventricularly delivering the compound.
37. (New) A method according to claim 14, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.
38. (New) A method according to claim 14, wherein said administering step further comprises delivering the compound to the subject through a catheter.
39. (New) A method according to claim 35, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.